Commercializing Cell and Gene Therapies

By Xcenda

Clinically promising, commercially challenging. Discover the go-to-market strategies to succeed when the patient is in the supply chain.
Topics:
Cell and Gene Therapy Commercialization

Related Content

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

Xcenda
May 2020

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Xcenda
August 2019

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.